Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.British drug maker AstraZeneca has launched Brilinta (ticagrelor) tablets in the US following the approval from the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
The drug is used for the reduction of rate of thrombotic cardiovascular (CV) events in patients suffering from acute coronary syndrome (ACS).
Brilinta has demonstrated reduction in the rate of a combined end point of CV death, MI, or stroke compared to clopidogrel in previous trials.
AstraZeneca Brilinta Clinical Development executive director Alex Gold said the US approval and launch of Brilinta means that physicians now have access to a new treatment option for patients with ACS that is proven to be more effective than clopidogrel at reducing heart attack and cardiovascular death when taken with low-dose aspirin (less than 100mg).